VANCOUVER, Feb. 21, 2013 /CNW/ - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CNSX: FLU), announces the engagement of Triangle Consultants to represent Abattis at the various government levels across Canada.
Mr. Mike Withrow, Chief Executive Officer on behalf of the Company, stated, "We are pleased to have a team of seasoned and experienced professionals who are Triangle Consultants working in government regulations and policies on our behalf." Mr. Withrow went on to state, "We are confident in the capabilities that Triangle brings to Abattis and believe they will achieve all of the milestones we have established for them."
Mr. Norm Vocino, President of Triangle Consultants, stated, "We are pleased to be working with Abattis in helping them attain their future goals and objectives", continued Mr. Vocino, "We look forward to putting our unique and strategic business approach as well as the expertise and resources of Triangle Consultants, into this exciting opportunity".
About Triangle Consultants
Triangle consultants is a boutique consulting firm specializing in providing valuable advice, strategies and direction for a wide variety of private and public companies and organizations. Our approach enables our clients to unlock the full potential of their opportunities. Through our extensive experience and network, we are able to quickly assess our client's needs and develop a unique and strategic path forward.
About Abattis Bioceuticals Corp.
Abattis Bioceuticals Corp. is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of producing, licensing and marketing proprietary ingredients and bio-similar compounds for use in Pharmaceuticals, Nutraceutical, Cosmetic and Animal Nutrition markets. The company also has a deep pipeline of proprietary products ready for sale in high growth areas of Functional Foods and Supplements business. For more information, visit the Company's website at www.abattis.com.
ON BEHALF OF THE BOARD
President & CEO
Neither the CNSX Exchange nor its regulations services accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Abattis Bioceuticals Corp.
For further information: